{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T20:29:13Z","timestamp":1776630553971,"version":"3.51.2"},"reference-count":49,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["molpharm.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Pharmacology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1124\/mol.114.097451","type":"journal-article","created":{"date-parts":[[2015,6,25]],"date-time":"2015-06-25T01:26:01Z","timestamp":1435195561000},"page":"477-487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Lysosomal Sequestration Determines Intracellular Imatinib Levels"],"prefix":"10.1016","volume":"88","author":[{"given":"Herman","family":"Burger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander T.","family":"den Dekker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Segeletz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonius W.M.","family":"Boersma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"de Bruijn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Debiec-Rychter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Sleijfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Sparreboom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron H.J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erik A.C.","family":"Wiemer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/mol.114.097451_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2012.10.015","article-title":"Polymorphisms in OCTN1 and OCTN2 transporters genes are associated with prolonged time to progression in unresectable gastrointestinal stromal tumours treated with imatinib therapy","volume":"68","author":"Angelini","year":"2013","journal-title":"Pharmacol Res"},{"key":"10.1124\/mol.114.097451_bib2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.3324\/haematol.2012.066480","article-title":"Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy","volume":"98","author":"Angelini","year":"2013","journal-title":"Haematologica"},{"key":"10.1124\/mol.114.097451_bib3","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells","volume":"119","author":"Bellodi","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1124\/mol.114.097451_bib4","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1007\/s11095-007-9278-4","article-title":"Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar","volume":"24","author":"Bihorel","year":"2007","journal-title":"Pharm Res"},{"key":"10.1124\/mol.114.097451_bib5","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1038\/leu.2013.13","article-title":"From in vitro to in vivo: intracellular determination of imatinib and nilotinib may be related with clinical outcome","volume":"27","author":"Bouchet","year":"2013","journal-title":"Leukemia"},{"key":"10.1124\/mol.114.097451_bib6","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1002\/cyto.a.22118","article-title":"Measurement of imatinib uptake by flow cytometry","volume":"81","author":"Bourgne","year":"2012","journal-title":"Cytometry A"},{"key":"10.1124\/mol.114.097451_bib7","doi-asserted-by":"crossref","first-page":"4965","DOI":"10.1182\/blood-2013-03-493841","article-title":"Can \u201cspecific\u201d OCT1 inhibitors be used to determine OCT1 transporter activity toward imatinib?","volume":"121","author":"Burger","year":"2013","journal-title":"Blood"},{"key":"10.1124\/mol.114.097451_bib8","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.4161\/cc.3.12.1331","article-title":"Pharmacokinetic resistance to imatinib mesylate: role of the ABC drug pumps ABCG2 (BCRP) and ABCB1 (MDR1) in the oral bioavailability of imatinib","volume":"3","author":"Burger","year":"2004","journal-title":"Cell Cycle"},{"key":"10.1124\/mol.114.097451_bib9","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1182\/blood-2004-04-1398","article-title":"Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)\/ABCG2 drug pump","volume":"104","author":"Burger","year":"2004","journal-title":"Blood"},{"key":"10.1124\/mol.114.097451_bib10","doi-asserted-by":"crossref","first-page":"747","DOI":"10.4161\/cbt.4.7.1826","article-title":"Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps","volume":"4","author":"Burger","year":"2005","journal-title":"Cancer Biol Ther"},{"key":"10.1124\/mol.114.097451_bib11","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1111\/j.1476-5381.2009.00569.x","article-title":"Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2)","volume":"159","author":"Burger","year":"2010","journal-title":"Br J Pharmacol"},{"key":"10.1124\/mol.114.097451_bib12","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.3324\/haematol.2009.008631","article-title":"ABC transporter A3 facilitates lysosomal sequestration of imatinib and modulates susceptibility of chronic myeloid leukemia cell lines to this drug","volume":"94","author":"Chapuy","year":"2009","journal-title":"Haematologica"},{"key":"10.1124\/mol.114.097451_bib13","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1182\/blood-2005-02-0694","article-title":"hOCT 1 and resistance to imatinib","volume":"106","author":"Crossman","year":"2005","journal-title":"Blood"},{"key":"10.1124\/mol.114.097451_bib14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1089\/omi.2008.0086","article-title":"Genome-wide identification of genes required for yeast growth under imatinib stress: vacuolar H+-ATPase function is an important target of this anticancer drug","volume":"13","author":"dos Santos","year":"2009","journal-title":"OMICS"},{"key":"10.1124\/mol.114.097451_bib15","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/1078-0432.CCR-10-2250","article-title":"Drug transporters and imatinib treatment: implications for clinical practice","volume":"17","author":"Eechoute","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1124\/mol.114.097451_bib16","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1158\/1535-7163.MCT-13-0084","article-title":"Sunitinib and SU11652 inhibit acid sphingomyelinase, destabilize lysosomes, and inhibit multidrug resistance","volume":"12","author":"Ellegaard","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/mol.114.097451_bib17","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/sj.leu.2404606","article-title":"The anticancer drug imatinib induces cellular autophagy","volume":"21","author":"Ertmer","year":"2007","journal-title":"Leukemia"},{"key":"10.1124\/mol.114.097451_bib18","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nrm2272","article-title":"Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology","volume":"8","author":"Forgac","year":"2007","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1124\/mol.114.097451_bib19","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/nchem.1961","article-title":"Imaging the intracellular distribution of tyrosine kinase inhibitors in living cells with quantitative hyperspectral stimulated Raman scattering","volume":"6","author":"Fu","year":"2014","journal-title":"Nat Chem"},{"key":"10.1124\/mol.114.097451_bib20","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.canlet.2010.05.021","article-title":"Combating apoptosis and multidrug resistant cancers by targeting lysosomes","volume":"332","author":"Groth-Pedersen","year":"2013","journal-title":"Cancer Lett"},{"key":"10.1124\/mol.114.097451_bib21","doi-asserted-by":"crossref","first-page":"14333","DOI":"10.1073\/pnas.1000248107","article-title":"Autophagy inhibition and antimalarials promote cell death in gastrointestinal stromal tumor (GIST)","volume":"107","author":"Gupta","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/mol.114.097451_bib22","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1177\/0192623311419524","article-title":"A multifaceted evaluation of imatinib-induced cardiotoxicity in the rat","volume":"39","author":"Herman","year":"2011","journal-title":"Toxicol Pathol"},{"key":"10.1124\/mol.114.097451_bib23","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-07-4913","article-title":"Interaction of imatinib with human organic ion carriers","volume":"14","author":"Hu","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1124\/mol.114.097451_bib24","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/toxsci\/kfs192","article-title":"Mechanistic investigation of imatinib-induced cardiac toxicity and the involvement of c-Abl kinase","volume":"129","author":"Hu","year":"2012","journal-title":"Toxicol Sci"},{"key":"10.1124\/mol.114.097451_bib25","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/jps.20792","article-title":"Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications","volume":"96","author":"Kaufmann","year":"2007","journal-title":"J Pharm Sci"},{"key":"10.1124\/mol.114.097451_bib26","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate","volume":"12","author":"Kerkel\u00e4","year":"2006","journal-title":"Nat Med"},{"key":"10.1124\/mol.114.097451_bib27","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/jcp.22112","article-title":"Lipophilic cationic drugs increase the permeability of lysosomal membranes in a cell culture system","volume":"224","author":"Kornhuber","year":"2010","journal-title":"J Cell Physiol"},{"key":"10.1124\/mol.114.097451_bib28","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s00280-003-0741-6","article-title":"Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588","volume":"53","author":"le Coutre","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1124\/mol.114.097451_bib29","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"key":"10.1124\/mol.114.097451_bib30","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0005-2736(91)90238-4","article-title":"Omeprazole and bafilomycin, two proton pump inhibitors: differentiation of their effects on gastric, kidney and bone H(+)-translocating ATPases","volume":"1065","author":"Mattsson","year":"1991","journal-title":"Biochim Biophys Acta"},{"key":"10.1124\/mol.114.097451_bib31","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1182\/blood-2009-03-210732","article-title":"A gene expression signature of CD34+ cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib","volume":"115","author":"McWeeney","year":"2010","journal-title":"Blood"},{"key":"10.1124\/mol.114.097451_bib32","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1158\/1535-7163.MCT-10-0731","article-title":"Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins","volume":"10","author":"Minematsu","year":"2011","journal-title":"Mol Cancer Ther"},{"key":"10.1124\/mol.114.097451_bib33","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.tiv.2010.12.010","article-title":"A high content screening assay for identifying lysosomotropic compounds","volume":"25","author":"Nadanaciva","year":"2011","journal-title":"Toxicol In Vitro"},{"key":"10.1124\/mol.114.097451_bib34","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1158\/1078-0432.CCR-13-1999","article-title":"Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1)","volume":"20","author":"Nies","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1124\/mol.114.097451_bib35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10637-008-9138-z","article-title":"The effect of P-gp (Mdr1a\/1b), BCRP (Bcrp1) and P-gp\/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib","volume":"27","author":"Oostendorp","year":"2009","journal-title":"Invest New Drugs"},{"key":"10.1124\/mol.114.097451_bib36","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/leu.2009.233","article-title":"Cathepsin B release after imatinib-mediated lysosomal membrane permeabilization triggers BCR-ABL cleavage and elimination of chronic myelogenous leukemia cells","volume":"24","author":"Puissant","year":"2010","journal-title":"Leukemia"},{"key":"10.1124\/mol.114.097451_bib37","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1021\/jm049546c","article-title":"Acid-base profiling of imatinib (gleevec) and its fragments","volume":"48","author":"Szak\u00e1cs","year":"2005","journal-title":"J Med Chem"},{"key":"10.1124\/mol.114.097451_bib38","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.1182\/blood-2003-12-4276","article-title":"Active transport of imatinib into and out of cells: implications for drug resistance","volume":"104","author":"Thomas","year":"2004","journal-title":"Blood"},{"key":"10.1124\/mol.114.097451_bib39","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/sj.clpt.6100268","article-title":"Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia","volume":"83","author":"Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/mol.114.097451_bib40","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1200\/JCO.2009.26.5819","article-title":"Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib","volume":"28","author":"White","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1124\/mol.114.097451_bib41","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1200\/JCO.2011.41.1090","article-title":"Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response","volume":"30","author":"White","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1124\/mol.114.097451_bib42","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3324\/haematol.2011.056457","article-title":"Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib","volume":"97","author":"White","year":"2012","journal-title":"Haematologica"},{"key":"10.1124\/mol.114.097451_bib43","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood-2007-06-093617","article-title":"Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity","volume":"110","author":"White","year":"2007","journal-title":"Blood"},{"key":"10.1124\/mol.114.097451_bib44","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2005-11-4687","article-title":"OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib","volume":"108","author":"White","year":"2006","journal-title":"Blood"},{"key":"10.1124\/mol.114.097451_bib45","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1038\/sj.leu.2404671","article-title":"Resistance reversal by RNAi silencing of MDR1 in CML cells associated with increase in imatinib intracellular levels","volume":"21","author":"Widmer","year":"2007","journal-title":"Leukemia"},{"key":"10.1124\/mol.114.097451_bib46","first-page":"244","article-title":"Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia","volume":"33","author":"Yamakawa","year":"2011","journal-title":"Ther Drug Monit"},{"key":"10.1124\/mol.114.097451_bib47","doi-asserted-by":"crossref","first-page":"12485","DOI":"10.1073\/pnas.1207821109","article-title":"Dopamine receptor D3 regulates endocytic sorting by a Prazosin-sensitive interaction with the coatomer COPI","volume":"109","author":"Zhang","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1124\/mol.114.097451_bib48","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1158\/1078-0432.CCR-12-3306","article-title":"Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide","volume":"19","author":"Zimmerman","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1124\/mol.114.097451_bib49","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1038\/sj.leu.2403853","article-title":"Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia","volume":"19","author":"Zong","year":"2005","journal-title":"Leukemia"}],"container-title":["Molecular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24031638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026895X24031638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/mol.114.097451","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T10:09:20Z","timestamp":1739959760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026895X24031638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0026895X24031638"],"URL":"https:\/\/doi.org\/10.1124\/mol.114.097451","relation":{},"ISSN":["0026-895X"],"issn-type":[{"value":"0026-895X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lysosomal Sequestration Determines Intracellular Imatinib Levels","name":"articletitle","label":"Article Title"},{"value":"Molecular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/mol.114.097451","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}